jun 4, 2018: 4 p.m. - 5 p.m.
Room 210B, Level 2
Living cells can carry out functions that cannot be performed by conventional drug treatments such as small molecules, biologics, antibodies and recombinant proteins. As conventional treatments generally engage or replace a single molecular target, their effect is often limited to the ability to address one molecular dysfunction. In contrast, cells can be engineered to generate living medicines that have the potential to compensate for the dysfunction of entire processes or pathways missing in disease and/or required for health.
Attendees will hear how researchers and companies are working to exploit the therapeutic potential of different types of engineered cells ranging from hemaptopoietic stem cells to beneficial probiotic bacteria with the intent of developing novel medicines to treat a wide array of diseases.
Ability Level: All